TRV734
 | |
| Identifiers | |
|---|---|
| |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C22H28FN3O |
| Molar mass | 369.484 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
TRV734 is a drug developed by Trevena Inc which acts as a biased agonist at the μ-opioid receptor, selective for activation of the G-protein signalling pathway over β-arrestin 2 recruitment. It is closely related to oliceridine and has a similar pharmacological profile, but unlike oliceridine which has to be injected, TRV734 is suitable to be administered orally.[1]
See also
[edit]References
[edit]- ^ James IE, Skobieranda F, Soergel DG, Ramos KA, Ruff D, Fossler MJ (February 2020). "A First-in-Human Clinical Study With TRV734, an Orally Bioavailable G-Protein-Biased Ligand at the μ-Opioid Receptor". Clinical Pharmacology in Drug Development. 9 (2): 256–266. doi:10.1002/cpdd.721. PMID 31286645. S2CID 195843184.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |